| Followers | 3 |
| Posts | 1176 |
| Boards Moderated | 0 |
| Alias Born | 03/02/2018 |
Wednesday, March 06, 2019 8:40:48 AM
I don't and never have grasped at straws
to make any negative observation about Delcath company.
I made money on that fluke spike as well. I rode it from
.02 to.30.
I then became over-enthusiastic and bought back-in.
Afterwards, more thorough and ongoing research and investigation of the company made it perfectly clear that there was no need to grasp at straws in order to inhale the stench of something rotten in Delcath.
I made a bad re-investment decision and that was a lesson learned. My lack of due diligence in that matter does Not excuse their operating tactics.
Risk is involved in any investment but that brand of 'acceptable' risk is separate from the risk of fraudulent behavior and willful mismanagement.
I don't regret the lesson learned with lost money...and I won't refrain from digging-up the dirt on this company. I'll merely refrain from posting all new evidence as I agreed to do.
Besides, every investor can research and investigate in order to uncover and/or 'profit' from the treasure to be found with a little time and elbow grease.
.
to make any negative observation about Delcath company.
I made money on that fluke spike as well. I rode it from
.02 to.30.
I then became over-enthusiastic and bought back-in.
Afterwards, more thorough and ongoing research and investigation of the company made it perfectly clear that there was no need to grasp at straws in order to inhale the stench of something rotten in Delcath.
I made a bad re-investment decision and that was a lesson learned. My lack of due diligence in that matter does Not excuse their operating tactics.
Risk is involved in any investment but that brand of 'acceptable' risk is separate from the risk of fraudulent behavior and willful mismanagement.
I don't regret the lesson learned with lost money...and I won't refrain from digging-up the dirt on this company. I'll merely refrain from posting all new evidence as I agreed to do.
Besides, every investor can research and investigate in order to uncover and/or 'profit' from the treasure to be found with a little time and elbow grease.
.
Recent DCTH News
- Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference • Business Wire • 05/12/2026 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2026 01:09:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2026 12:12:12 PM
- Delcath Systems Reports First Quarter 2026 Results and Business Highlights • Business Wire • 05/07/2026 12:00:00 PM
- Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026 • Business Wire • 05/07/2026 11:00:00 AM
- Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 04/27/2026 08:12:24 PM
- Delcath Systems to Host First Quarter 2026 Earnings Call • Business Wire • 04/23/2026 12:30:00 PM
- Delcath Systems, Inc. Announces Inclusion of CHEMOSAT Hepatic Delivery System for Melphalan as a Recommended Liver-Directed Regional Therapy Option in the ESMO–EURACAN Clinical Practice Guidelines for Uveal Melanoma • Business Wire • 04/06/2026 12:30:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/02/2026 12:56:15 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 04/02/2026 12:55:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/02/2026 12:52:52 PM
- Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting • Business Wire • 04/01/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2026 09:22:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/03/2026 09:48:16 PM
- Delcath Systems Announces Publication of CHOPIN Clinical Trial Results in The Lancet Oncology • Business Wire • 03/03/2026 01:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/26/2026 02:15:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/26/2026 01:06:06 PM
- Delcath Systems Reports Fourth Quarter and Full Year 2025 Results • Business Wire • 02/26/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:14 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:13 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:11 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:08 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/19/2026 02:30:05 AM
